The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

Industry leaders delve into the latest biopharma supply chain disruptions and provide insights into approaches that can help to reduce vulnerabilities and ensure greater resilience in the future.

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

In this white paper, Chris Gilmor, Director of Sales, Sanner America, introduces the company’s new packaging platform, TabTec® CR, which is a convenient solution for oral solid dosage products with integrated desiccant and child-resistant opening.

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.

Digital systems, automation, and flexibility are crucial for overcoming the hurdles associated with the development and manufacture of next-gen therapies, but ongoing investment is critical to ensure continued innovation in the sector.

Affordability and accessibility are critical factors for commercial success of next-gen therapies; however, greater industry collaboration is needed to reduce inefficiencies in the development of advanced technologies.

In this interview, David Phasey from 3P innovation highlights why advanced technologies are critical to helping companies overcome the challenges associated with the development and manufacture of next-generation therapies.

Despite the numerous challenges facing the development, manufacture, and commercialization of next-generation therapies, the end value proposition they offer is significant and worth the effort from stakeholders.

With digitalization gaining traction in biomanufacturing, The Pharma Navigator speaks to experts about how digital twins and advanced modeling are helping companies meet industry demands and what that means for the workforce.

While meaningful progress has been made by the biopharmaceutical industry into digitalization, there is still a lot of work to do to achieve a true digital transformation.

The grant money will be used by the biotechs to develop innovative targeted lipid nanoparticles that contain novel immune-silent DNA constructs for in vivo CAR T therapy.